Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results | Zendy

Nancy E. Kemeny | Zendy; Lawrence H. Schwartz | Zendy; Mithat Gönen | Zendy; Adam C. Yopp | Zendy; David H. Gültekin | Zendy; Michael I. D’Angelica | Zendy; Yuman Fong | Zendy; Dana Haviland | Zendy; Alexandra N. Gewirtz | Zendy; Peter J. Allen | Zendy; William R. Jarnagin | Zendy

Open Access

Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results

Author(s) -

Nancy E. Kemeny,

Lawrence H. Schwartz,

Mithat Gönen,

Adam C. Yopp,

David H. Gültekin,

Michael I. D’Angelica,

Yuman Fong,

Dana Haviland,

Alexandra N. Gewirtz,

Peter J. Allen,

William R. Jarnagin

Publication year - 2011

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000324704

Subject(s) - medicine , bevacizumab , gastroenterology , floxuridine , dexamethasone , hepatic arterial infusion , population , hepatocellular carcinoma , toxicity , chemotherapy , cancer , fluorouracil , colorectal cancer , environmental health

This study investigated the efficacy and safety of adding systemic (IV) bevacizumab (Bev) to hepatic arterial infusion (HAI) with floxuridine (FUDR)/dexamethasone (Dex) in unresectable primary liver cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research